SynthesisJournal of thrombosis and haemostasis : JTH2022
Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: A systematic review.
Synthesis in Journal of thrombosis and haemostasis : JTH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis.European heart journal · 2026Pooled it
- SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Net clinical benefit of DOACs vs. usual anticoagulation treatment in venous thromboembolism and active cancer: systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2023Pooled it
- Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: A systematic review.Journal of thrombosis and haemostasis : JTH · 2022Pooled it
- API-CAT investigators' decisions on anticoagulation following extended treatment for cancer-associated thrombosis.European heart journal. Cardiovascular pharmacotherapy · 2026Trial
- Antithrombotic therapy at the end-of-life-continue or stop?Research and practice in thrombosis and haemostasis · 2026Review
- Case Report: Upper extremity deep vein thrombosis revealing an occult invasive ductal breast carcinoma.Frontiers in cardiovascular medicine · 2026Article
- Economic Evaluation of Direct Oral Anticoagulants Versus Low-Molecular Weight Heparin for Cancer-Associated Thrombosis in a Thai University-Affiliated Hospital.Journal of clinical medicine · 2025Article
- Anticoagulants in hematologic malignancies: what is the data?Hematology. American Society of Hematology. Education Program · 2025Review
- Long term anticoagulation for Catheter-Related deep vein thrombosis of the upper extremities in women with cancer: retrospective analysis of effectiveness and safety outcomes.Journal of thrombosis and thrombolysis · 2025Article
- Observational
- The current status and future perspective of extended anticoagulation therapy for cancer-associated venous thromboembolism.Journal of thrombosis and thrombolysis · 2025Review
- Cancer-associated venous thromboembolism: a comprehensive review.Thrombosis journal · 2025Review
- Factors associated with thrombosis among solid organ cancer patients in Kuala Lumpur, Malaysia.Thrombosis journal · 2025Article
- Article
- Significantly higher incidence of circulating fatty objects in portal blood samples compared to peripheral blood samples in patients with pancreatic ductal adenocarcinoma.Frontiers in oncology · 2025Article
- Emerging Biomarkers for Assessing Thrombotic Risk in Patients Receiving Direct Oral Anticoagulants (DOACs).Cardiovascular & hematological agents in medicinal chemistry · 2025Review
- Treatment of VTE in the thrombocytopenic cancer patient.Hematology. American Society of Hematology. Education Program · 2024Review
- Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer.EBioMedicine · 2024Article
- An epidemiologic study comparing cancer- and noncancer-associated venous thromboembolism in a racially diverse Southeastern United States county.Research and practice in thrombosis and haemostasis · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with cancer-associated venous thromboembolism (VTE) are recommended to receive treatment with therapeutic anticoagulation for at least 3-6 months. Little data exist on extended treatment beyond 6 months.
objectiveTo comprehensively summarize the best available evidence on incidence of recurrent VTE and major bleeding 6-12 months after the index event in patients with cancer-associated VTE. PATIENTS/
methodsWe systematically screened biomedical databases (MEDLINE, Embase, CENTRAL) to identify studies reporting recurrent VTE and/or bleeding events between 6 and 12 months after a diagnosis of cancer-associated VTE. Based on the observed heterogeneity in study design, setting, patient cohort characteristics, anticoagulation strategies, and outcome rates, no overall quantitative estimate of outcome rates was calculated.
resultsWe screened 2597 publications and identified 11 eligible studies matching predefined in-/exclusion criteria, reporting on 3019 patients specifically during the 6- to 12-month period post-index VTE. Overall rates of recurrent VTE in this timeframe varied substantially (1%-12%), with the highest risk observed in the patient subgroup with residual vein thrombosis present at 6 months randomized to receive no anticoagulation (13%-15%). Reported rates of major bleeding between 6 and 12 months were between 2% and 5%.
conclusionsIn this systematic review, we provide a comprehensive and structured summary of the best available evidence on recurrence and bleeding risk between 6 and 12 months after cancer-associated VTE. VTE recurrence remains common beyond 6 months and continuation of different anticoagulation strategies has an acceptable safety profile indicated by lower bleeding rates. These findings support guideline recommendations to continue anticoagulation treatment beyond 6 months in patients with active cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.